PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.71%
Revenue growth under 50% of AVGO's 6.32%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.96%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-912.75%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-912.75%
Negative operating income growth while AVGO is at 1.00%. Joel Greenblatt would press for urgent turnaround measures.
-1025.69%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-966.67%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-966.67%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.68%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-9.15%
Reduced diluted shares while AVGO is at 0.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
13562.28%
OCF growth above 1.5x AVGO's 9.32%. David Dodd would confirm a clear edge in underlying cash generation.
420.66%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
240.58%
10Y revenue/share CAGR at 50-75% of AVGO's 416.86%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
240.58%
5Y revenue/share CAGR above 1.5x AVGO's 134.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
240.58%
3Y revenue/share CAGR above 1.5x AVGO's 62.33%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
567.31%
10Y OCF/share CAGR in line with AVGO's 580.47%. Walter Schloss would see both as similarly efficient over the decade.
567.31%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
567.31%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-452.26%
Negative 10Y net income/share CAGR while AVGO is at 869.72%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-452.26%
Negative 5Y net income/share CAGR while AVGO is 414.43%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-452.26%
Negative 3Y CAGR while AVGO is 16.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
586.03%
10Y equity/share CAGR at 50-75% of AVGO's 862.23%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
586.03%
5Y equity/share CAGR above 1.5x AVGO's 165.61%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
586.03%
3Y equity/share CAGR above 1.5x AVGO's 201.93%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.65%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-28.14%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
0.90%
Asset growth 1.25-1.5x AVGO's 0.60%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
-1.15%
We have a declining book value while AVGO shows 5.15%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.51%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
0.96%
R&D dropping or stable vs. AVGO's 13.26%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
7.76%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.